RecruitingPhase 3

A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis

United States, United Kingdom15 participantsStarted 2026-02

Plain-language summary

The purpose of this study is to evaluate the efficacy and safety of Coagadex in treating active bleeds and to manage peri-operative bleeding in participants with acquired factor X deficiency associated with AL amyloidosis.

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Male or female participants ages 18-70 years old.
✓. Diagnosis of aFXD associated with AL amyloidosis with FX:C ≤ 50 IU/dL.
✓. Woman of Childbearing Potential (defined in Appendix 2) and men of reproductive potential who agree to use an effective contraception measure during the study.

Exclusion criteria

✕. Female participants that are pregnant or lactating.
✕. Presence of FX inhibitors.
✕. Uncontrolled arterial hypertension.
✕. On anticoagulant therapy (not antiplatelets), unstable heart disease, clinically significant thrombotic event in the past 180 days or any other condition that the Investigator believes is likely to interfere with evaluation of the study drug or with satisfactory conduct of the trial.
✕. Any factor X containing product taken within 2 weeks of first Coagadex® administration.
✕. Participation in another interventional clinical study with an investigational drug, biologic, or device within 30 days prior to screening.
✕. Hemodynamically unstable due to any cause or even after blood transfusion, fluid resuscitation and pharmacologic or volume replacement pressor therapy.
✕. Prior history of bleeding disorder other than aFXD.

What they're measuring

Proportion of bleeding events responsive to Coagdex® therapy at 72 hours after initiation of treatment in the On-Demand Treatment Cohort

Timeframe: at 72 hours

Proportion of bleeding events responsive to Coagdex® therapy at 72 hours after initiation of treatment in the Surgery/Invasive Procedures Cohort

Timeframe: at 72 hours

Trial details

NCT IDNCT06963216

SponsorKedrion S.p.A.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2027-06

Contact for this trial

Nicola Rovai

+39 335 6524750 n.rovai@kedrion.com

View on ClinicalTrials.gov More Acquired Factor X Deficiency trials

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Male or female participants ages 18-70 years old.
✓. Diagnosis of aFXD associated with AL amyloidosis with FX:C ≤ 50 IU/dL.
✓. Woman of Childbearing Potential (defined in Appendix 2) and men of reproductive potential who agree to use an effective contraception measure during the study.

Exclusion criteria

✕. Female participants that are pregnant or lactating.
✕. Presence of FX inhibitors.
✕. Uncontrolled arterial hypertension.
✕. On anticoagulant therapy (not antiplatelets), unstable heart disease, clinically significant thrombotic event in the past 180 days or any other condition that the Investigator believes is likely to interfere with evaluation of the study drug or with satisfactory conduct of the trial.
✕. Any factor X containing product taken within 2 weeks of first Coagadex® administration.
✕. Participation in another interventional clinical study with an investigational drug, biologic, or device within 30 days prior to screening.
✕. Hemodynamically unstable due to any cause or even after blood transfusion, fluid resuscitation and pharmacologic or volume replacement pressor therapy.
✕. Prior history of bleeding disorder other than aFXD.

What they're measuring

Proportion of bleeding events responsive to Coagdex® therapy at 72 hours after initiation of treatment in the On-Demand Treatment Cohort

Timeframe: at 72 hours

Proportion of bleeding events responsive to Coagdex® therapy at 72 hours after initiation of treatment in the Surgery/Invasive Procedures Cohort

Timeframe: at 72 hours